Volpara Health Technologies is revolutionising breast cancer detection. Tim Boreham investigates
Cancer detection biotech Radiopharm Theronostics is planning to list on the Nasdaq, and not without good reason, Tim Boreham explains
It’s impossible to picture a future without cybersecurity. The ASX hosts a smorgasboard in potential exposures
Tim Boreham highlights the global addressable market opportunity for Avita Medical’s skin graft technology, made famous by the Bali bombings
Tapping into the Scandinavian market, Helloworld has acquired an interest in Norway-based Australiareiser, bringing its ResWorld platform to Europe
Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development
Amidst a sea of red, the Neuren share price has skyrocketed in recent days following a world first approval for the biotech’s treatment of Rett syndrome
Tim Boreham gets his teeth into the opportunity ahead for listed dental products company SDI
IVE Group continues to prove its strong market position, lifting guidance as integration of Ovato outperforms over the first half
Countering inflation by lifting prices seems easier-said-than-done for many a small-cap food producer, reports Tim Boreham